Oral cancer: comorbidity status, immune biomarkers predict survival

  • Jariod-Ferrer ÚM & al.
  • J Oral Maxillofac Surg
  • 19 Mar 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Comorbidity status and immune biomarkers predict survival in patients with resectable oral squamous cell carcinoma (OSCC).

Why this matters

  • This study further supports observed associations between comorbidity status and mortality in patients with OSCC.

Key results

  • 1-year OS was 88%, 3-year OS was 68%, and 5-year OS was 57%.
  • 73.9% of patients had ≥1 comorbidity.
  • Moderate (HR, 2.36; P=.041) and severe (HR, 4.04; P=.004) comorbidity status (Adult Comorbidity Evaluation-27 scale), as well as age >80 years (HR, 3.84; P=.001), therapeutic neck dissection (HR, 2.95; P=.010 vs elective neck dissection), and close/positive margins (HR, 1.91; P=.028), were associated with poor OS in multivariate analysis.
  • The neutrophile-to-lymphocyte ratio (NLR), derived NLR (dNLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) had 64.4%, 61.4%, 77.3%, and 56.2% diagnostic performance (area under the receiver operating characteristic curve) for predicting OS.
    • Optimal cutoff points of 3 for NLR, 1.9 for dNLR, 2.6 for LMR, and 66 for PLR were identified.
    • None of these markers was significantly associated with OS in multivariate analysis.

Study design

  • 215 patients with resectable OSCC were included.
  • Funding: None disclosed.

Limitations

  • Retrospective study.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit